Real-world evidence on patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) long-term survival after treatment with liposomal irinoteca
Phase 4
Recruiting
- Conditions
- Metastatic pancreatic ductal adenocarcinoma (mPDAC)
- Registration Number
- JPRN-UMIN000051641
- Lead Sponsor
- Servier Affaires Medicales
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients meeting any of the following criteria will not be included in the study: 1. No documentation of systemic therapy outcomes or prior treatments in patient medical records 2. Patients with second concomitant metastatic malignancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot Applicable as data collection is performed to describe population, disease and treatment characteristics.
- Secondary Outcome Measures
Name Time Method ot Applicable as data collection is performed to describe population, disease and treatment characteristics.